Background: Advanced recurrent/metastatic cervical cancer has a 5-year survival of only 17%
Introduction
Cervical cancer is a common cancer in women, with an estimated 570,000 new cases globally in 2018, and represents the third-leading cause of cancer-related death in women worldwide. 1 Recurrent/metastatic cervical cancer (r/mCC) has a poor prognosis, with a 5-year survival rate of 17%. 2 Bevacizumab and doublet chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) was adopted as first-line (1L) standard-of-care therapy for r/mCC in the past 5 years. [3] [4] [5] However, nearly all patients relapse after 1L, and single institution experiences indicate that the percentage of patients who receive a second-line (2L) therapy varies (30-70%) as many patients die before receiving treatment. 6, 7 Available 2L+ therapies for r/mCC are characterized by low response rates. 4, 5 Before adoption of bevacizumab+doublet chemotherapy in 1L, therapies administered in the 2L+ setting reported response rates in the range of 4.5-15%, with median survival <8 months. [8] [9] [10] [11] [12] [13] [14] Data in the postbevacizumab+chemotherapy setting are limited, with a single-institution study showing singledigit response rates (0-6%) for 2L treatment, 6 suggesting prior vascular endothelial growth factor inhibition may negatively impact subsequent treatment response. Data in the third-line setting are further limited, with ≈60% of patients not receiving third-line treatment and, when treated, response rates of 3%. 7 Recently, pembrolizumab (anti-programmed death 1) was granted and immediate need for effective therapies that provide clinical benefit in a broader patient population.
Tisotumab vedotin (TV) is a first-in-class antibody-drug conjugate (ADC) composed of a tissue factor (TF)-specific, fully human monoclonal antibody conjugated to the clinically validated microtubule-disrupting agent monomethyl auristatin E (MMAE). 16, 17 Under normal physiological conditions, TF is central to the coagulation pathway. 18 In oncogenesis, TF plays a role in tumor-associated angiogenesis, progression, and metastasis. [19] [20] [21] [22] TF is aberrantly expressed across many solid tumors, including cervical cancer, 21, [23] [24] [25] and has been associated with poor clinical outcomes. 21 The expression of TF across tumor types and its role in oncogenesis makes it an appealing therapeutic target.
TV delivers MMAE to TF-expressing cells to induce direct cytotoxicity and bystander killing of neighboring cells. 16, 17 In vitro studies demonstrated that TV induces immunogenic cell death (ICD) and efficiently engages with immune cells to promote tumor cell death through Fcγ receptor-mediated effector functions, such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). 17, 26 Moreover, TV was found to inhibit TF-activated factor VII (FVIIa)-dependent intracellular signaling, while minimally impacting procoagulant activity. 17 To our knowledge, TV is the first and only drug to successfully target TF.
innovaTV 201 (NCT02001623) is a phase 1/2 dose-escalation and expansion trial evaluating TV in patients with previously treated locally advanced or metastatic solid tumors. In the dose-escalation phase, TV showed a manageable safety profile, and 2.0 mg/kg every 3 weeks was established as the recommended phase 2 dose. 27 Here, we report the safety and antitumor activity of TV in the cervical cancer expansion cohort.
Methods

Study Oversight
Genmab A/S sponsored the study, provided study drug, and collaborated with academic investigators on study design, data analysis/interpretation, and manuscript writing. The trial was conducted in accordance with the International Conference on Harmonization Good Clinical Practice Guidelines, Declaration of Helsinki, and all applicable regulatory requirements. The trial protocol was approved by an independent ethics committee or institutional review board prior to initiation. All patients gave written informed consent. All authors confirm the accuracy of the data and adherence of the trial to the protocol.
Study Design and Patients
innovaTV 201 is an open-label, multi-cohort, phase 1/2 dose escalation and expansion study of TV in locally advanced and/or metastatic solid tumors known to express TF. The design of the innovaTV 201 study has been previously described (additional details in the Supplementary Appendix).
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A protocol amendment expanded the cervical cancer cohort to enroll a maximum of 55 patients in order to better characterize the activity and tolerability of TV in this population. 
Study Outcomes
The primary objective of this study was to evaluate the safety and tolerability of TV. Key secondary endpoints included ORR (defined as complete response [CR] or partial response [PR] as assessed by the investigator or IRC), duration of response (DOR), and progression-free survival (PFS) per RECIST v1.1.
Statistical Analyses
All patients who received at least one dose of TV were included in the safety and antitumor activity analyses. ORR was determined with a corresponding two-sided 95% exact binomial confidence interval (CI). IRC-assessment utilized a 2+1 adjudication method. Agreement between investigator-and IRC-assessment with respect to confirmed objective response was determined using Cohen's kappa. Median PFS and DOR were determined using the KaplanMeier method and presented with a two-sided 95% CI. Prespecified subgroup factors included TF expression. Association between TF expression and response was analyzed using analysis of variance with Tukey's multi-comparison post hoc test.
Results
Patients
Between November 2015, and April 2018, a total of 55 patients were enrolled into the cervical cancer expansion cohort of the innovaTV 201 study ( Figure S1 ). The demographics and baseline disease characteristics are presented in Table 1 . Most patients had ECOG performance status of 1 (73%). 51% of the patients had squamous cell carcinoma and 35% had adenocarcinoma. 51%
received ≥2 prior lines of treatment. Four patients did not receive 1L standard-of-care therapy because they were refractory to treatment for early stage disease (concurrent chemoradiation or neoadjuvant therapy) and were considered as having zero prior lines of treatment in the recurrent setting. Prior systemic therapies received included taxanes (91%) and bevacizumab+doublet chemotherapy (67%). TF expression (≥1%) was confirmed in the majority of evaluable patients (membrane expression, 100%; cytoplasmic expression, 96%).
Safety
At data cutoff (September 30, 2018), the median follow-up was 3.5 months (range, 0.6-11.8).
The median number of doses of TV received was 4.0 (range, 1.0-14.0). Ten patients (18%) discontinued treatment due to an AE, the most common of which was peripheral neuropathy (9%). Seven patients (13%) had an AE leading to dose reduction (Table S1 ).
Treatment-emergent AEs regardless of causality and of any grade were reported in all patients,
and AEs of grade ≥3 were reported in 31 patients (56%) ( Table 2 ). The most common AEs were epistaxis (51%), fatigue (51%), nausea (49%), conjunctivitis (42%), and alopecia (40%) ( Table   2 ). Of these, most were grade 1/2. The most common grade ≥3 AEs were anemia (11%), fatigue (9%), and vomiting (7%). Twenty-nine patients (53%) had serious AEs (Table S2) , the most common of which were vomiting (7%) and constipation (5%). Two fatal events occurred while on treatment, both due to disease progression, and were assessed as unrelated to treatment by investigator and study sponsor. No treatment-related deaths were observed.
No grade ≥4 AESIs were observed. Neuropathy AESIs occurred in 30 patients (55%), 6 of which (11%) were grade 3, and the most common was peripheral neuropathy (36%; grade 3, 4%) ( Table 2, Table S3 ). Seventeen patients (31%) had neuropathy at baseline. Bleeding-related
AESIs occurred in 40 patients (73%) and most were grade 1/2, with three patients (5%) experiencing a grade 3 bleeding-related event (two with vaginal hemorrhage and one with hematuria) ( Table 2, Table S4 ). The most common bleeding-related event was epistaxis (51%); all were grade 1 except for one grade 2. Ocular AESIs of any type occurred in 36 patients (65%), and the most common were conjunctivitis (42%) and dry eye (24%) ( Table 2, Table S5 ). The incidence of ocular events was reduced from 80% in patients enrolled prior to the implementation of mitigation measures (n=15) to 60% in patients enrolled after implementation (n=40). The rates of conjunctivitis were reduced from 80% to 28% ( Figure S2 ).
Antitumor Activity
The investigator-assessed confirmed ORR was 24% (95% CI, 13−37) ( Table 3) . Maximum changes in target lesion size from baseline are shown in Figure 1A . The median time to response (TTR) was 2.6 months (range, 1.1−3.9) and the median DOR was 4.2 months (range, 1.0 + −9.7)
( Table 3) . Four patients experienced a confirmed PR for >8 months ( Figure 1B) . The median ( Figure S3 ).
The IRC-assessed confirmed ORR was 22% (95% CI, 12−35) ( Table 3) . One patient had CR by IRC-assessment. The overall agreement between investigator-and IRC-assessment with respect to ORR was 95% (Cohen's kappa 0.84). The median IRC-assessed DOR was 6.0 months (range,
, and the 6-month PFS rate was 40% (95% CI, 24−55) ( Table 3 , Figure S4 ). Figure 1C shows the target and non-target lesion baseline and follow-up scans of a 43-year-old female patient with squamous cell carcinoma previously treated with paclitaxel+carboplatin.
This patient achieved PR after 16 weeks of treatment and discontinued TV due to an AE at that time. The decreased target lesion size persisted after treatment discontinuation up to week 47.
Subgroup and Biomarker Analysis
Investigator-assessed responses with TV were observed across histologic types (squamous cell has been demonstrated in the ocular epithelium, 31, 32 which may result in treatment-emergent toxicity in these cells. The understanding of TF-related epistaxis and ocular events is continuing to evolve, and further studies are needed to optimize mitigation strategies, as well as to assess the long-term effects of TV, the duration of these AESIs, and the mechanisms by which they occur.
The ORR observed with TV across histological types, line of therapy, and prior treatments, including bevacizumab+doublet chemotherapy, is clinically important in a patient population The majority of cervical cancer patient biopsies had detectable TF expression. Although median membrane and cytoplasmic TF H-score was higher in patients who achieved PR and SD compared to those with progressive disease, there was no statistically significant association with best confirmed response. That said, the majority of samples were from archival tissue, and the effect of previous lines of therapy on TF expression has yet to be explored.
This study demonstrated the antitumor activity of TV in patients with advanced, previously treated r/mCC. However, overall survival was not a specified endpoint, and thus further studies 
Data Sharing Statement
The de-identified data that support the findings of this study are available on request to bona fide researchers who provide a methodologically sound proposal. The data will be made available 24 months following study completion. Proposals should be directed to the corresponding author. To gain access, data requestors will need to sign a data access agreement. ǁ Positive TF expression was defined as ≥1%; percentage prevalence was calculated out of TF expression evaluable population (n=46). CR, n (%) 0 1 (2) PR, n (%) 13 (24) 11 (20) SD, n (%) 21 (38) 19 (35) Non-CR/Non-PD, n (%) 0 2 (4) PD, n (%) 17 (31) 17 (31) Not evaluable, n (%) 4 (7) 5 (9) Median TTR (range), months 2.6 (1. 
Supplementary Methods
The dose escalation phase of the innovaTV 201 study followed a standard 3+3 design to evaluate tisotumab vedotin at doses of 0.3 mg/kg up to 2.2 mg/kg administered intravenously every 3
weeks. The dose of tisotumab vedotin used in the expansion cohort was based on the safety and efficacy data from the dose escalation phase.
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The expansion phase included patients with locally advanced and/or metastatic cervical, ovarian, prostate, bladder, esophageal, endometrial, and non-small cell lung cancer who have progressed on or are ineligible for standard treatments. 27 The cervical and ovarian cancer cohorts were expanded from the initial 14 patients to approximately 30 patients each based on preliminary clinical activity and safety observed. After an amendment to the protocol, up to an additional 25 patients could be enrolled in the cervical cancer cohort for a maximum of 55 patients in total. 
